DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/1dc050/the_hiv_market_out) has announced the addition of the "The HIV Market Outlook to 2016" report to their offering.
This report provides comprehensive coverage of the HIV market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the HIV market. It also identifies products in late stage development and forecasts their expected sales performance.
Features and benefits
- Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
- Compare the franchises of the leading companies in HIV, and understand how the market share of these companies will change.
- Evaluate pipeline compounds for the treatment of HIV and determine which products will provide the greatest revenue growth.
- Understand the market dynamics and interactions between the key drug classes used in the treatment of HIV.
- Forecast the performance of the leading marketed and pipeline products through to 2016.
Highlights
In terms of sales, the US dominated the global HIV market, accounting for just over 50% of sales in 2010. Collectively, the leading pharmaceutical markets of the EU were the second largest HIV market with a market share of just over 33%. The countries with very high endemicity of HIV actually only account for very small market shares.
The current market for HIV treatment is dominated by once-daily regimens. There is a strong trend towards regimen simplification and reduced pill burden, which has resulted in the rapid penetration of several once daily treatment options. To this end Gilead is developing a Quad Pill which contains four active ingredients the first such product.
Gilead was the leading company in the 2010 recording sales of over $6bn at a Y-o-Y growth of over 13%. Gilead's performance in 2010 was very strong, capturing over 35% of the global HIV market. This strong performance was largely due to the company's leading NRTI product, Atripla which posted 2010 sales of $3bn at a Y-o-Y growth of 22.9%.
For more information visit http://www.researchandmarkets.com/research/1dc050/the_hiv_market_out.
Source: Business Insights